Recombinant therapeutic monoclonal antibodies: Mechanisms of action in relation to structural and functional duality

Critical Reviews in Oncology/Hematology

Volumn 64, Issue 3, 2007, Pages 226-233

  Congy Jolivet, Nicolas ^a,b   Probst, Alicia ^a,b   Watier, Hervé ^a,b   Thibault, Gilles ^a,b  

^a UNIVERSITÉ DE TOURS   (France)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

ADCC; CDC; Fab; Fc; Mechanism of action; Naked monoclonal recombinant antibody

Indexed keywords

ABCIXIMAB; ALEMTUZUMAB; BEVACIZUMAB; CETUXIMAB; COMPLEMENT COMPONENT C1Q; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; INFLIXIMAB; MAPATUMUMAB; MATUZUMAB; MEMBRANE ANTIGEN; MITUMOMAB; MONOCLONAL ANTIBODY; NIMOTUZUMAB; PANITUMUMAB; PERTUZUMAB; RECOMBINANT ANTIBODY; RITUXIMAB; TGN 1412; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ANTIGEN FUNCTION; ANTIGEN RECOGNITION; APOPTOSIS; DRUG MECHANISM; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; NONHUMAN; PROTEIN EXPRESSION; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN FC FRAGMENTS; MODELS, BIOLOGICAL; NEOPLASMS; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 35648996524     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2007.06.013     Document Type: Review

References (68)

1. Köhler G., and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 5517 (1975) 495-497
2. Hagenbeek A. Radioimmunotherapy for NHL: experience of 90Y-ibritumomab tiuxetan in clinical practice. Leuk Lymphoma 44 4 (2003) S37-S47
3. ®: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non Hodgkin's lymphoma. Oncologist 9 2 (2004) 160-172
4. Hamann P.R., Hinman L.M., Hollander I., et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 13 1 (2002) 47-58
5. Clark M. Antibody humanization: a case of the "Emperor's new clothes"?. Immunol Today 21 8 (2000) 397-402
6. Lobo E.D., Hansen R.J., and Balthasar J.P. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93 11 (2004) 2645-2668
7. Alegre M.L., and Fallarino F. Mechanisms of CTLA-4-Ig in tolerance induction. Curr Pharm Des 12 2 (2006) 149-160
8. Olsen N.J., and Stein C.M. New drugs for rheumatoid arthritis. N Engl J Med 350 21 (2004) 2167-2179
9. Presta L.G., Chen H., O'Connor S.J., et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57 20 (1997) 4593-4599
10. Muller Y.A., Chen Y., Christinger H.W., et al. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. Structure 6 9 (1998) 1153-1167
11. Volk W.A., Bizzini B., Snyder R.M., Bernhard E., and Wagner R.R. Neutralization of tetanus toxin by distinct monoclonal antibodies binding to multiple epitopes on the toxin molecule. Infect Immun 45 3 (1984) 604-609
12. Nowakowski A., Wang C., Powers D.B., et al. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci USA 99 17 (2002) 11346-11350
13. McGuiness C.R., and Mantis J.M. Characterization of a novel hight affinity monoclonal immunoglobulin G antibody against th Ricin B subunit. Infect Immun 74 6 (2006) 3463-3470
14. +-channel toxins protects against experimental scorpion envenoming. Cell Mol Life Sci 64 2 (2007) 206-218
15. Garcia-Rodriguez C., Levy R., Arndt J.W., et al. Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat Biotechnol 25 1 (2007) 107-116
16. Presta L. Evolving an anti-toxin antibody. Nat Biotechnol 46 1 (2007) 77-83
17. Tonra J.R., Deevi D.S., Corcoran E., et al. Sygnergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res 12 7Pt1 (2006) 2197-2207
18. Coller B.S. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 76 1 (1985) 101-108
19. Goldstein N.I., Prewett M., Zuklys K., Rockwell P., and Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1 11 (1995) 1311-1318
20. Veronese M.L., and O'Dwyer P.J. Monoclonal antibodies in the treatment of colorectal cancer. Eur J Cancer 40 9 (2004) 1292-1301
21. Crombet-Ramos T., Rak J., Perez R., and Viloria-Petit A. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. Int J Cancer 101 6 (2002) 567-575
22. Sridhar S.S., Seymour L., and Shepherd F.A. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 4 7 (2003) 397-406
23. Cho H.S., Mason K., Ramyar K.X., et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421 6924 (2003) 756-760
24. Franklin M.C., Carey K.D., Vajdos F.F., Leahy D.J., de Vos A.M., and Sliwkowski M.X. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5 4 (2004) 317-328
25. Keyhanfar M., Forbes B.E., Cosgrove L.J., Wallace J.C., and Booker G.W. Production and characterization of monoclonal antibodies against insulin-like growth factor type 1 receptor. Hybridoma 25 4 (2006) 230-237
26. Pukac L., Kanakaraj P., Humphreys R., et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 92 8 (2005) 1430-1441
27. Suntharalingam G., Perry M.R., Ward S., et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355 10 (2006) 1018-1028
28. Kenter M.J., and Cohen A.F. Establishing risk of human experimentation with drugs: lessons from TGN1412. Lancet 368 9544 (2006) 1387-1391
29. Barnes M.R., Holbrook J., Field J.A., Searls D.B., and Sanseau P. Risk in drug trials. Lancet 368 9554 (2006) 2205
30. Ohresser M., Olive D., Vanhove B., and Watier H. Risk in drugs trials. Lancet 368 9554 (2006) 2205-2206
31. Loisel S., Ohresser M., Pallardy M., et al. Relevance, advantages and limitations of animal models used in the developpement of monoclonal antibodies for cancer treatment. Crit Rev Oncol Hematol 62 1 (2007) 34-42
32. Cartron G., Watier H., Golay J., and Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 104 9 (2004) 2635-2642
33. Semac I., Palomba C., Kulangara K., et al. Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells. Cancer Res 63 (2003) 534-540
34. Hofmeister J.K., Cooney D., and Coggeshall K.M. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis 26 2 (2000) 133-143
35. Byrd J.C., Kitada S., Flinn I.W., et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 99 3 (2002) 1038-1043
36. Lieberman J. The ABCS of granule-mediated cytotoxicity: new weapons in the arsenal. Nat Rev Immunol 3 5 (2003) 361-370
37. Chan H.T., Hughes D., French R.R., et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res 63 17 (2003) 5480-5489
38. Van der Kolk L.E., Evers L.M., Omene C., et al. CD20-induced B cell death can bypass mitochondria and caspase activation. Leukemia 16 9 (2002) 1735-1744
39. Mounier N., Briere J., Gisselbrecht C., et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101 11 (2003) 4279-4284
40. Shan D., Gopal A.K., and Press O.W. Synergistic effects of the fenretinide (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells. Clin Cancer Res 7 8 (2001) 2490-2495
41. Ghetie M.A., Bright H., and Vitetta E.S. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 97 5 (2001) 1392-1398
42. Di Gaetano N., Xiao Y., Erba E., et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 114 4 (2001) 800-809
43. Rose A.L., Smith B.E., and Maloney D.G. Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood 100 5 (2002) 1765-1773
44. Alas S., Ng C.P., and Bonavida B. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma. Clin Cancer Res 8 3 (2002) 836-845
45. Alas S., Emmanouilides C., and Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 7 3 (2001) 709-723
46. Alas S., and Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 61 13 (2001) 5137-5144
47. Anderson D.R., Grillo-Lopez A.J., Varns C., Chambers K.S., and Hanna N. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans 25 2 (1997) 705-708
48. Chapman P.B., Wu D., Ragupathi G., et al. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside. Clin Can Res 10 14 (2004) 4717-4723
49. Greenwood J., Clark M., and Waldmann H. Structural motifs involved in human IgG antibody effector functions. Eur J Immunol 23 5 (1993) 1098-1104
50. Reff M.E., Carner K., Chambers K.S., et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83 2 (1994) 435-445
51. ®). Semin Oncol 26 4 Suppl. 12 (1999) 60-70
52. Teeling J.L., French R.R., Cragg M.S., et al. Characterization of a new CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104 6 (2004) 1793-1800
53. Teeling J.L., Mackus W.J., Wiegman L.J., et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes in CD20. J Immunol 177 1 (2006) 362-371
54. Manches O., Lui G., Chaperot L., et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 101 3 (2003) 949-954
55. Bienvenu J., Chvetzoff R., Salles G., et al. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. Hematol J 2 6 (2001) 378-384
56. Van der Kolk L.E., Grillo-Lopez A.J., Baars J.W., Hack C.E., and van Oers M.H. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 115 4 (2001) 807-811
57. Kennedy A.D., Solga M.D., Schuman T.A., et al. An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. Blood 101 3 (2003) 1071-1079
58. Di Gaetano N., Cittera E., Nota R., et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 171 3 (2003) 1581-1587
59. Clynes R.A., Towers T.L., Presta L.G., and Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6 4 (2000) 443-446
60. Dall'Ozzo S., Tartas S., Paintaud G., et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 64 13 (2004) 4664-4669
61. Cooley S., Burns L.J., Repka T., and Miller J.S. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp Hematol 27 10 (1999) 1533-1541
62. Cartron G., Dacheux L., Salles G., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99 3 (2002) 754-758
63. Weng W.K., and Levy R. Two immunoglobulin G Fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21 21 (2003) 3940-3947
64. Treon S.P., Hansen M., Branagan A.R., et al. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol 23 3 (2005) 474-481
65. Anolik J.H., Campbell D., Felgar R.E., et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48 2 (2003) 455-459
66. Louis E., El Ghoul Z., Vermeire S., et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther 19 5 (2004) 511-519
67. Watier H. Variability factors in the clinical response to recombinant antibodies and IgG Fc-containing fusion proteins. Expert Opin Biol Ther 5 1 (2005) 29-36
68. Edberg J.C., and Kimberly R.P. Cell type-specific glycoforms of Fc gamma RIIIa (CD16): differential ligand binding. J Immunol 100 5 (1997) 1059-1070